Table 1 Patient characteristics.
From: Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
Number of patients (%) | |
|---|---|
Sex | |
Male | 53 (58) |
Female | 39 (42) |
Median age (years) | 59 (range 21–86) |
FAB classification | |
M0 | 9 (10) |
M1 | 22 (24) |
M2 | 16 (17) |
M3 | 6 (7) |
M4 | 17 (18) |
M5 | 21 (23) |
Not classified | 1 (1) |
WHO classification | |
AML with recurrent genetic abnormalities | 55 (60) |
AML with myelodysplasia-related changes | 11 (12) |
Therapy-related myeloid neoplasms | 3 (2) |
Myeloid neoplasms with germline predisposition | 0 (0) |
AML. not otherwise specified | 24 (26) |
Primary/secondary AML | |
Primary | 70 (76) |
Secondary | 22 (24) |
Blood count (median) | |
WBC (G/L) | 56.9 (range 4.6–448.3) |
Hb (g/dl) | 8.6 (range 4.4–12.9) |
Plt (G/L) | 43.5 (range 6–252) |
NCCN risk score distribution | |
Favorable | 33 (36) |
Intermediate | 36 (39) |
Poor | 16 (17) |
Not classified | 7 (8) |
Genetic abberations | |
t(15;17) | 6 (6) |
inv(16) | 4 (4) |
FLT3-ITD | 28 (26) |
FLT3-TKD | 5 (5) |
NPM1 | 24 (21) |
CEBPA | 6 (6) |
MLL-AF9 | 2 (2) |
IDH 2 | 6 (6) |
